Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 2:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 3,262 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo first Clear all
Completed Not applicable Interventional Results available

Cognitive Dysfunction in Parkinson's Disease

NCT02346708
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Real TMS, Sham TMS
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Nov 12, 2026, 2:14 AM EST
Completed Phase 3 Interventional Results available

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)

NCT04249076
View directory record Official record
Conditions
Cataract
Interventions
Clobetasol Propionate, Vehicle
Drug
Lead sponsor
Salvat
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Sun City, Arizona • Hemet, California • Inglewood, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Nov 12, 2026, 2:14 AM EST
Recruiting Phase 2Phase 3 Interventional

Gabapentin to Reduce Opioid Use Postoperatively (GROUP) in Children

NCT04724252
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Gabapentin, Placebo
Drug · Other
Lead sponsor
University of California, Davis
Other
Eligibility
Up to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 12, 2026, 2:14 AM EST
Active, not recruiting Phase 2 Interventional

Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV

NCT06691243
View directory record Official record
Conditions
Cocaine Use Disorder, HIV
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Nov 12, 2026, 2:14 AM EST
Withdrawn Phase 2 Interventional

A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy

NCT02036463
View directory record Official record
Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
Prednisone, Placebo
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
3 Years to 6 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Nov 12, 2026, 2:14 AM EST
Completed Phase 2 Interventional

Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients

NCT02763033
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation
Interventions
Bob's Red Mill®, Starch Placebo
Drug · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
10 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Nov 12, 2026, 2:14 AM EST
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study of Acarbose in Longevity

NCT02953093
View directory record Official record
Conditions
Aging
Interventions
Acarbose, Placebo
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
60 Years to 100 Years · Male only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Nov 12, 2026, 2:14 AM EST
Completed Not applicable Interventional

Effect of Whole Blueberry Powder Consumption on Depression in a Central Louisiana Population

NCT04398784
View directory record Official record
Conditions
Depression, Depression, Anxiety, Inflammation
Interventions
Freeze Dried Blueberry Powder - 71717, USHBC Blueberry Placebo Formula #114
Dietary Supplement
Lead sponsor
Louisiana State University, Baton Rouge
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Cottonport, Louisiana • Marksville, Louisiana
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Nov 12, 2026, 2:14 AM EST
Completed Phase 1 Interventional

Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study

NCT02096965
View directory record Official record
Conditions
Nephrolithiasis, Calcium Oxalate, Nephrolithiasis, Calcium Phosphate
Interventions
Tolvaptan, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Nov 12, 2026, 2:14 AM EST
Not listed Phase 4 Interventional

Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension

NCT01468571
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Nov 12, 2026, 2:14 AM EST
Completed Phase 2 Interventional Results available

Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine

NCT02571049
View directory record Official record
Conditions
Rapidly Escalating Migraine
Interventions
DFN-11
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited, India
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Nov 12, 2026, 2:14 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Heart Rate Variability Biofeedback: It's Role in Asthma Therapeutics

NCT02766374
View directory record Official record
Conditions
Asthma
Interventions
Heart rate variability biofeedback, Placebo
Behavioral
Lead sponsor
Fred Wamboldt, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
2
States / cities
Denver, Colorado • Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Nov 12, 2026, 2:14 AM EST
Terminated Phase 3 Interventional Results available

Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC

NCT02954159
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Tacrolimus, Vedolizumab, Placebo
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Nov 12, 2026, 2:14 AM EST
Completed Phase 2 Interventional Results available

A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection

NCT01147302
View directory record Official record
Conditions
Graft Rejection
Interventions
Placebo, C1 Esterase Inhibitor (Human)
Biological
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Nov 12, 2026, 2:14 AM EST
Completed Phase 3 Interventional Results available

Inhaled Nitric Oxide in Brain Injury

NCT03260569
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Inhaled Nitric Oxide, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Nov 12, 2026, 2:14 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects

NCT01364441
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
ONO-2952, Placebo
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Nov 12, 2026, 2:14 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects

NCT01530022
View directory record Official record
Conditions
Healthy
Interventions
Lacosamide (LCM), Carbamazepine Immediate Release (CBZ-IR)
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Atlanta, Georgia • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Nov 12, 2026, 2:14 AM EST
Withdrawn Phase 2 Interventional

A Pilot Feasibility Study of IM OXT on Fear of Pain and Trust in Physical Therapist During OP Rehabilitation After TKA

NCT04493229
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Nov 12, 2026, 2:14 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2373 After Single Dose Administration in Healthy Male Subjects of African Ancestry.

NCT04269031
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD2373 subcutaneous injection, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Nov 12, 2026, 2:14 AM EST
Recruiting Phase 2 Interventional

Donepezil and Cognitive Training for Alcohol Use Disorder (AUD)

NCT05042102
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Donepezil + Cognitive remediation therapy (CRT), Donepezil + Placebo CRT, Placebo medication + Cognitive remediation therapy (CRT), Placebo medication + Placebo CRT
Combination Product
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 12, 2026, 2:14 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation

NCT00833495
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Prednisolone Acetate 0.12% (Pred Mild®), FOV1101-00, Prednisolone Acetate 1% (Pred Forte®), Placebo
Drug
Lead sponsor
Fovea Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Nov 12, 2026, 2:14 AM EST
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period

NCT05175105
View directory record Official record
Conditions
Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia
Interventions
Mitapivat, Mitapivat-matching placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
11
States / cities
Palo Alto, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 12, 2026, 2:14 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3848575 in Healthy Participants

NCT05727072
View directory record Official record
Conditions
Healthy
Interventions
LY3848575, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Nov 12, 2026, 2:14 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

GSK706769 A First Time in Human Study For Males and Females

NCT00539201
View directory record Official record
Conditions
Healthy Subjects
Interventions
GSK706769
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 19, 2010 · Synced Nov 12, 2026, 2:14 AM EST